SCHEMBL968125

SCHEMBL968125

NNC(=O)Cc1ccncc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.62
CYP3A4 P08684 2/20 0.62
CYP2C9 P11712 1/20 0.62
ALDH1A1 P00352 1/20 0.56
GAA P10253 1/20 0.56
MAPT P10636 1/20 0.56
KDM4E B2RXH2 1/20 0.55
MPO P05164 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2A6 P11509 1/20 0.55
CYP2C19 P33261 1/20 0.55
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA5A P35218 2/20 0.53
CA7 P43166 2/20 0.53
CA5B Q9Y2D0 2/20 0.53
AOC2 O75106 3/20 0.51
RAB9A P51151 2/20 0.50
NPC1 O15118 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6870708 0.98 CYP1A2 (0.61) CYP1A2CYP3A4CYP2C9ALDH1A1GAA
SCHEMBL11796135 0.84 AOC2 (0.66) CYP1A2CYP3A4CYP2C9GAAAOC2
SCHEMBL7817965 0.80 LMNA (0.56) CYP1A2CYP3A4CYP2C9ALDH1A1GAA
SCHEMBL24015949 0.79 ALDH1A1 (0.56) ALDH1A1GAAMAPTCA1CA2
SCHEMBL3413933 0.79 ALDH1A1 (0.56) ALDH1A1GAAMAPTCA1CA2
SCHEMBL19387994 0.79 RAB9A (0.58) ALDH1A1GAAMAPTKDM4ECA1
SCHEMBL5080 0.78 MEN1 (0.65) CYP1A2CYP3A4CYP2C9ALDH1A1GAA
SCHEMBL967538 0.77 CYP3A4 (1.00) CYP1A2CYP3A4CYP2C9ALDH1A1GAA
SCHEMBL7814720 0.77 CYP1A2 (0.48) CYP1A2CYP3A4CYP2C9ALDH1A1GAA
SCHEMBL10288964 0.77 GAA (0.58) ALDH1A1GAAMAPTKDM4ECA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5011932-A Anthelmintic pyridinyl acylhydrazones derivatives UPJOHN COMPANY (US) 1991-04-30 US claimed
EP-0214158-A1 ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1987-03-18 EP claimed
WO-1986004582-A1 ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1986-08-14 WO claimed
EP-3541802-B1 ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2025-01-01 EP disclosed
US-12110285-B2 Substituted pyridine derivatives as SARM1 inhibitors NURA BIO, INC. (US) 2024-10-08 US disclosed
US-12110293-B2 Substituted triazolo quinoxaline derivatives Grünenthal GmbH (DE) 2024-10-08 US disclosed
CN-114989156-B Receptor interaction protein inhibitor and preparation method and application thereof 成都贝诺科成生物科技有限公司 2024-07-05 CN disclosed
EP-4376840-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS Nura Bio, Inc. (US) 2024-06-05 EP disclosed
CN-118043046-A Substituted pyridine derivatives as SARM1 inhibitors 努拉生物公司 2024-05-14 CN disclosed
CN-112673009-B Substituted triazoloquinoxaline derivatives 格吕伦塔尔有限公司 2023-09-19 CN disclosed
US-20230286941-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. 2023-09-14 US disclosed
EP-0694545-A2 Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use G.D. SEARLE & CO. (US) 1996-01-31 EP disclosed
EP-0694546-A2 Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use G.D. SEARLE & CO. (US) 1996-01-31 EP disclosed
US-5464830-A ANALGESICS G. D. SEARLE & CO. (US) 1995-11-07 US disclosed
US-5378840-A Substituted dibenzoxazepine compounds G. D. SEARLE & CO. (US) 1995-01-03 US disclosed
EP-0583421-A1 SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE G.D. SEARLE & CO. (US) 1994-02-23 EP disclosed
WO-1992019617-A2 SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE G.D. SEARLE & CO. (US) 1992-11-12 WO disclosed
EP-0512400-A1 Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use G.D. Searle & Co. (US) 1992-11-11 EP disclosed
EP-0214158-A1 ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1987-03-18 EP disclosed
WO-1986004582-A1 ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1986-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12110285-B2 Substituted pyridine derivatives as SARM1 inhibitors SARM1, SARNP, ADRM1 CYP1A2 4096/4885CYP3A4 4237/4885CYP2C9 4761/4885
US-20230286941-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS SARM1, SARNP, ADRM1 CYP1A2 4096/4885CYP3A4 4237/4885CYP2C9 4761/4885
US-12110293-B2 Substituted triazolo quinoxaline derivatives NR3C1, NR3C2, GRK5 CYP1A2 168/4885CYP3A4 301/4885CYP2C9 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.